Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 13 of 13 · 376 total
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The petitioner asserts that U.S. Patent No. 11,679,077 is invalid due to anticipation and obviousness over multiple prior art references in the field of nasal therapy. The core arguments focus on how Saadat anticipates key claims, while combinations of Makower, Fang, and Edwards-535 render other claims obvious.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
NEURENT MEDICAL INC. successfully petitioned PTAB for institution of IPR against THE FOUNDRY, LLC's nasal cavity treatment patent (11679077). The Board found sufficient evidence across multiple grounds of anticipation and obviousness to proceed to trial.
NEURENT MEDICAL INC. et al. v.The Foundry, LLC et al.
The Petitioner successfully demonstrated that multiple claims of the '077 patent were unpatentable over various combinations of prior art references. The Board found that a Person Having Ordinary Skill in the Art (POSA) would have been motivated to combine existing RF ablation and nasal treatment technologies.
3Shape A/S et al. v.Dental Imaging Technologies Corporation
Petitioner asserts that the challenged dental imaging claims are obvious over various combinations of prior art references, including Sommer, Rubbert, Malfliet, and Estépar. The petition details how specific elements related to bite registration methods merely aggregate known technologies from these sources.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom, Inc. initiated this IPR petition against Abbott Diabetes Care Inc.'s patent, challenging multiple claims based on obviousness. The core argument is that the patented features are merely predictable combinations of prior art references (Stafford, Raymond, and Turner).
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.
VIVITRO LABS INC. v.BIOMEDICAL DEVICE CONSULTANTS & LABORATORIES OF COLORADO, LLC
Vivitro Labs and the patent owner settled their IPR dispute over a biomedical device patent, leading the Board to terminate the proceeding and keep the settlement confidential.
VIVITRO LABS INC. v.BIOMEDICAL DEVICE CONSULTANTS & LABORATORIES OF COLORADO, LLC
VIVITRO Labs and Biomedical Device Consultants & Laboratories of Colorado have settled their dispute over U.S. Patent 9,237,935, filing a joint motion to terminate the ongoing IPR and keep settlement documents confidential.
Ilooda Co., Ltd. et al. v.Serendia, LLC
The Board granted a joint motion to terminate the IPR as to Jeisys Medical Inc. following a settlement with Serendia, while allowing EndyMed petitioners to continue the review.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Serendia seeks Director Review to vacate the Board’s institution of an IPR against its dermatological device patent after the ITC upheld the patent’s validity. The request cites the recent recission of the Fintiv memo and extraordinary circumstances that favor a discretionary denial under § 314(a).
Ilooda Co., Ltd. et al. v.Serendia, LLC
Jeisys Medical Inc. and Serendia, LLC have settled their dispute over U.S. Patent 10,869,812. The parties filed a joint motion to terminate the inter partes review, citing the settlement and lack of substantive briefing.
Ilooda Co., Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia, LLC entered a settlement that resolved all disputes over three patents, leading the PTAB to terminate the associated IPRs. The settlement agreement was deemed confidential business information.
Ilooda Co., Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia, LLC filed a joint request to keep their settlement agreement confidential under 35 U.S.C. § 317(b) and related regulations. The request seeks to separate the agreement from the patent file and limit its disclosure.
Ilooda Co., Ltd. et al. v.Serendia, LLC
EndyMed Medical and Serendia have settled their dispute over U.S. Patent 10,869,812. The parties filed a joint motion to terminate the inter partes review, citing the settlement and lack of oral hearing. The Board is asked to dismiss the proceeding in its entirety.
Ilooda Co., Ltd. et al. v.Serendia, LLC
Serendia, LLC and Jeisys Medical Inc. jointly filed a request with the PTAB to keep their settlement agreement confidential and separate from the patent file, invoking 35 U.S.C. §317(b).
Ilooda Co., Ltd. et al. v.Serendia, LLC
Ilooda and Serendia have filed a joint motion to terminate Ilooda’s participation in an IPR over U.S. Patent 10,869,812, citing a settlement of their dispute. The Board has not yet ruled on institution, and the parties also request the settlement be kept confidential.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.